February 01, 2015 2:34 AM ET


Company Overview of ARCA biopharma, Inc.

Company Overview

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

11080 CirclePoint Road

Suite 140

Westminster, CO 80020

United States

14 Employees



Key Executives for ARCA biopharma, Inc.

Age: 69
Total Annual Compensation: $389.4K
Senior Vice President
Age: 55
Total Annual Compensation: $323.6K
Compensation as of Fiscal Year 2013.

ARCA biopharma, Inc. Key Developments

ARCA biopharma, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 11:30 AM

ARCA biopharma, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 11:30 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.

ARCA biopharma, Inc. Announces Activation of First Canadian Genetic-AF Clinical Trial Site

ARCA biopharma, Inc. announced the activation of the first GENETIC-AF clinical trial site in Canada. The site activation follows on the August 2014 acceptance by Health Canada of the company's Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation (AF). This site brings the total current number of active trial sites to thirty-three. ARCA plans to activate a total of approximately 60 clinical trial sites in the United States and Canada for the Phase 2B portion of the trial. ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is now enrolling patients in the United States and Canada. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation.

ARCA biopharma, Inc. Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola

ARCA biopharma, Inc. announced that the U.S. Food and Drug Administration(FDA) Office of Orphan Products Development has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus. The drug candidate has previously demonstrated post-exposure efficacy in non-human primate models of Ebola hemorrhagic fever virus (HFV). rNAPc2 was originally developed as a cardiovascular therapy for thrombosis and other indications. As a result, it has an extensive human clinical record, and has been safely tested in over 700 human patients in nine Phase 1 and 2 clinical trials for cardiovascular disease.

Similar Private Companies By Industry

Company Name Region
Sequella, Inc. United States
Argyll Biotechnologies, LLC United States
Unum Therapeutics, Inc. United States
Advanced Technologies and Regenerative Medicine, LLC United States
Olympus-Cytori, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARCA biopharma, Inc., please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.